Business Standard

Sun Pharma Q3 PAT doubles to Rs 1,852 cr, rides on record quarterly revenue

The company has repaid debt of about $490 million in 9MFY21; filings for 90 ANDAs await US FDA approval

Sun Pharma
Premium

Sohini Das Mumbai
Sun Pharmaceuticals posted a 9.2 percent year on year rise in consolidated sales from operations in the December quarter to Rs 8,782 crore, the highest ever quarterly sales posted by the company, while its net profit grew by 102.8 per cent to Rs 1,852 crore. 

The India sales grew by 9.4 per cent to Rs 2,753 crore while the US finished dosage sales came in at $374 mn, up 7 per cent YoY. The Ebitda was up 36.3 per cent over last year same period to Rs 2,351 crore with a resulting Ebitda margin of 26.8 per cent. 

Asserting that

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 29 2021 | 7:49 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com